(Q35728630)

9 August 2017

1 reference

title

Bortezomib and its role in the management of patients with multiple myeloma (English)

1 reference

9 August 2017

1

Robert Z Orlowski

1 reference

9 August 2017

1 April 2004

1 reference

Expert Review of Anticancer Therapy

9 August 2017

1 reference

9 August 2017

4

1 reference

9 August 2017

171-179

1 reference

9 August 2017

2

1 reference

The proteasome, a novel protease regulated by multiple mechanisms

9 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Potential for proteasome inhibition in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.2.171

21 January 2018

Identifiers

DOI

10.1586/14737140.4.2.171

1 reference

9 August 2017

1 reference

PubMed ID

15056047